title: Evaluation of cutaneous angioimmunoblastic T-cell lymphoma.
abstract: BACKGROUND
  Angioimmunoblastic T-cell lymphoma (AITL) accounts for 18% of peripheral T-cell lymphomas worldwide. Skin involvement occurs in up to 50% of patients but poses a diagnostic dilemma because of the limited number of reported cases and subsequent lack of established diagnostic criteria.
  
  
  OBJECTIVE
  The purpose of this review is to examine common clinical, histologic, and molecular findings in cases of AITL with the hope of improving the diagnostic accuracy of this challenging condition.
  
  
  METHODS
  We present a case of AITL and conducted a review of the literature.
  
  
  RESULTS
  The common clinical and histologic features in cases of AITL are nonspecific. However, newer immunohistochemical stains and gene rearrangement studies appear very promising at improving diagnostic capabilities.
  
  
  CONCLUSIONS
  There was a paucity of reported cases of AITL in the literature, and this review is retrospective.
  
  
  CONCLUSIONS
  AITL presents with nonspecific clinical and histologic findings, but immunohistochemical stains and gene rearrangements can help establish the diagnosis.
authors.affiliation: Washington University, Saint Louis, Missouri.
authors.forename: Brundha
authors.initials: B
authors.lastname: Balaraman
authors.affiliation: Washington University, Saint Louis, Missouri. Electronic address: jconley@dom.wustl.edu.
authors.forename: Jarod A
authors.initials: JA
authors.lastname: Conley
authors.affiliation: Washington University, Saint Louis, Missouri.
authors.forename: David M
authors.initials: DM
authors.lastname: Sheinbein
mesh_terms: D000368:Aged; D018771:Arthralgia / Q000175:diagnosis / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004167:Diphtheria Toxin / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000473:pathology; D015329:Gene Rearrangement, T-Lymphocyte; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy / Q000821:virology; D007376:Interleukin-2 / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy / Q000821:virology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011537:Pruritus / Q000175:diagnosis; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy / Q000821:virology; D033581:Stem Cell Transplantation; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D003841:Deoxycytidine; C078456:denileukin diftitox; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D000077235:Vinorelbine; D008727:Methotrexate; D000093542:Gemcitabine